We are excited to announce our partnership with Google Cloud to use their Natural Language Processing (NLP) technology to help us better understand the unstructured data in cancer patients’ medical records.
This is a key part of our mission to provide the most comprehensive cancer care possible by leveraging the latest advances in data science and technology.
COTA Announces New Financing from Deerfield Management and Prior Investors To Accelerate Cancer Research and Treatment Innovation
New financing will help COTA expand RWD platform & services to drive more efficient and inclusive drug development.
Deloitte’s new Real-World Evidence Survey reveals that life sciences companies are now using real-world data (RWD) and real-world evidence (RWE) throughout the product life cycle—from early discovery through commercialization.
Innovation is the key to success in the life sciences industry. But with the vast amounts of data being generated by clinical trials and other research, it can be difficult to know where to focus your efforts. COTA’s tailored, fit-for-purpose real-world data (RWD) can help.
COTA’s Summer Internship Program provides an opportunity for college students to explore their career interests, learn new skills, and receive mentorship from experts in the field. This year’s interns come from a variety of backgrounds and majors, and are working in a number of different areas within COTA.
As artificial intelligence revolutionizes healthcare, we must develop a regulatory framework to ensure ethical use of patient data for research and care delivery. But, what should those guardrails look like, and how will we deploy them across the life sciences and clinical care industries? Miruna Sasu shares her thoughts on AI in healthcare and its efficacy with patient data.
After working at one of the world’s leading global clinical research organizations, Noel joins us to continue his work advocating for patients and helping to advance therapeutic and diagnostic options for all.
COTA President & CEO, Miruna Sasu, gave a keynote speech at the DIA 2022 Global Annual Meeting on healthcare disparities. She shared her personal story of how her family benefited from clinical trials and how she is now working to open those opportunities for others.
We are so excited to welcome our 8 new interns for our 2022 internship program – learn a little bit more about each the newest additions to COTA.
COTA Research Showcased High Concordance Rate Between Real-World Physician Response Assessment & the 2017 European LeukemiaNet (ELN) Criteria for Acute Myeloid Leukemia at EHA2022
COTA researchers and collaborators’s recent abstract in the European Hematology Association’s library, found that overall agreement between response categories was 65.1% among AML data.